Glasdegib - Pfizer

Drug Profile

Glasdegib - Pfizer

Alternative Names: PF 04; PF-04449913; PF-4449913

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Netherlands Cancer Institute; Pfizer
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase II Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Phase I/II Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease
  • Phase I Cancer; Haematological malignancies
  • No development reported Solid tumours

Most Recent Events

  • 27 Jun 2018 Preregistration for Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA (PO)
  • 27 Jun 2018 FDA assigns PDUFA action date of December 2018 for glasdegib for Acute myeloid leukaemia (Combination therapy, First-line therapy)
  • 27 Jun 2018 The US FDA grants a Priority Review status for glasdegib's NDA in Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top